ASH News Daily 2016 - Issue 3 - A-13

CASCADE TRIAL:

Currently Enrolling Patients
With Acute Myeloid Leukemia
Vadastuximab Talirine (SGN-CD33A) Combined With Azacitidine or Decitabine in Older
Patients With Newly Diagnosed Acute Myeloid Leukemia (CASCADE)

Study Description
A phase 3, randomized, double-blind study of vadastuximab talirine (SGN-CD33A) in combination with azacitidine or
decitabine versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly
diagnosed acute myeloid leukemia.

Study Schema
Stratification
Factors for
Randomization
* Cytogenetic risk
* ECOG
* HMA
* Age

RANDOMIZATION

1:1

Vadastuximab
talirine + HMA in
4-week cycles

Primary
End Point:

Overall survival
Placebo + HMA
in 4-week cycles

ECOG, Eastern Cooperative Oncology Group; HMA, hypomethylating agent.

Follow-up: For patients who discontinue treatment prior to progression or leukemic recurrence, response assessments
continue every 2 months through 24 months. For all patients, survival status follow-up is every 2 months.

Mechanism of Action
Vadastuximab talirine (SGN-CD33A) is a highly potent, engineered antibody-drug conjugate (ADC) designed to deliver a
cytotoxic agent to CD33-expressing malignant myeloid cells.

Study Location
North America | Europe | South Korea | Taiwan | Israel |

Australia

Please call 866-333-7436 if you have a patient who may qualify for the CASCADE trial.
For additional information on this study, visit www.clinicaltrials.gov, identifier: NCT02785900.
Go to www.adc-cd33.com to learn more about ADC technology.
Vadastuximab talirine is an investigational agent, and its safety and efficacy have not been established.

© 2016 Seattle Genetics, Inc. All rights reserved. USM/33A/2016/0009 10/16



Table of Contents for the Digital Edition of ASH News Daily 2016 - Issue 3

ASH News Daily 2016 - Issue 3 - A-1
ASH News Daily 2016 - Issue 3 - A-2
ASH News Daily 2016 - Issue 3 - A-3
ASH News Daily 2016 - Issue 3 - A-4
ASH News Daily 2016 - Issue 3 - A-5
ASH News Daily 2016 - Issue 3 - A-6
ASH News Daily 2016 - Issue 3 - A-7
ASH News Daily 2016 - Issue 3 - A-8
ASH News Daily 2016 - Issue 3 - A-9
ASH News Daily 2016 - Issue 3 - A-10
ASH News Daily 2016 - Issue 3 - A-11
ASH News Daily 2016 - Issue 3 - A-12
ASH News Daily 2016 - Issue 3 - A-13
ASH News Daily 2016 - Issue 3 - A-14
ASH News Daily 2016 - Issue 3 - A-15
ASH News Daily 2016 - Issue 3 - A-16
ASH News Daily 2016 - Issue 3 - A-17
ASH News Daily 2016 - Issue 3 - A-18
ASH News Daily 2016 - Issue 3 - A-19
ASH News Daily 2016 - Issue 3 - A-20
ASH News Daily 2016 - Issue 3 - A-21
ASH News Daily 2016 - Issue 3 - A-22
ASH News Daily 2016 - Issue 3 - A-23
ASH News Daily 2016 - Issue 3 - A-24
ASH News Daily 2016 - Issue 3 - A-25
ASH News Daily 2016 - Issue 3 - A-26
ASH News Daily 2016 - Issue 3 - B-1
ASH News Daily 2016 - Issue 3 - B-2
ASH News Daily 2016 - Issue 3 - B-3
ASH News Daily 2016 - Issue 3 - B-4
ASH News Daily 2016 - Issue 3 - B-5
ASH News Daily 2016 - Issue 3 - B-6
ASH News Daily 2016 - Issue 3 - B-7
ASH News Daily 2016 - Issue 3 - B-8
ASH News Daily 2016 - Issue 3 - B-9
ASH News Daily 2016 - Issue 3 - B-10
ASH News Daily 2016 - Issue 3 - B-11
ASH News Daily 2016 - Issue 3 - B-12
ASH News Daily 2016 - Issue 3 - B-13
ASH News Daily 2016 - Issue 3 - B-14
ASH News Daily 2016 - Issue 3 - B-15
ASH News Daily 2016 - Issue 3 - B-16
ASH News Daily 2016 - Issue 3 - B-17
ASH News Daily 2016 - Issue 3 - B-18
ASH News Daily 2016 - Issue 3 - B-19
ASH News Daily 2016 - Issue 3 - B-20
ASH News Daily 2016 - Issue 3 - B-21
ASH News Daily 2016 - Issue 3 - B-22
ASH News Daily 2016 - Issue 3 - B-23
ASH News Daily 2016 - Issue 3 - B-24
ASH News Daily 2016 - Issue 3 - B-25
ASH News Daily 2016 - Issue 3 - B-26
ASH News Daily 2016 - Issue 3 - B-27
ASH News Daily 2016 - Issue 3 - B-28
ASH News Daily 2016 - Issue 3 - B-29
ASH News Daily 2016 - Issue 3 - B-30
ASH News Daily 2016 - Issue 3 - B-31
ASH News Daily 2016 - Issue 3 - B-32
ASH News Daily 2016 - Issue 3 - B-33
ASH News Daily 2016 - Issue 3 - B-34
ASH News Daily 2016 - Issue 3 - B-35
ASH News Daily 2016 - Issue 3 - B-36
ASH News Daily 2016 - Issue 3 - B-37
ASH News Daily 2016 - Issue 3 - B-38
ASH News Daily 2016 - Issue 3 - B-39
ASH News Daily 2016 - Issue 3 - B-40
ASH News Daily 2016 - Issue 3 - B-41
ASH News Daily 2016 - Issue 3 - B-42
ASH News Daily 2016 - Issue 3 - B-43
ASH News Daily 2016 - Issue 3 - B-44
ASH News Daily 2016 - Issue 3 - B-45
ASH News Daily 2016 - Issue 3 - B-46
ASH News Daily 2016 - Issue 3 - B-47
ASH News Daily 2016 - Issue 3 - B-48
ASH News Daily 2016 - Issue 3 - C-1
ASH News Daily 2016 - Issue 3 - C-2
ASH News Daily 2016 - Issue 3 - C-3
ASH News Daily 2016 - Issue 3 - C-4
ASH News Daily 2016 - Issue 3 - C-5
ASH News Daily 2016 - Issue 3 - C-6
ASH News Daily 2016 - Issue 3 - C-7
ASH News Daily 2016 - Issue 3 - C-8
ASH News Daily 2016 - Issue 3 - C-9
ASH News Daily 2016 - Issue 3 - C-10
ASH News Daily 2016 - Issue 3 - C-11
ASH News Daily 2016 - Issue 3 - C-12
ASH News Daily 2016 - Issue 3 - C-13
ASH News Daily 2016 - Issue 3 - C-14
ASH News Daily 2016 - Issue 3 - C-15
ASH News Daily 2016 - Issue 3 - C-16
ASH News Daily 2016 - Issue 3 - C-17
ASH News Daily 2016 - Issue 3 - C-18
ASH News Daily 2016 - Issue 3 - C-19
ASH News Daily 2016 - Issue 3 - C-20
ASH News Daily 2016 - Issue 3 - C-21
ASH News Daily 2016 - Issue 3 - C-22
ASH News Daily 2016 - Issue 3 - C-23
ASH News Daily 2016 - Issue 3 - C-24
ASH News Daily 2016 - Issue 3 - C-25
ASH News Daily 2016 - Issue 3 - C-26
https://www.nxtbookmedia.com